



Autonomic pharmacology







Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.




Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.

.----

	Muscle type	Ganglion type	CNS types		Notes
Main molecular form	$(\alpha 1)_2 \beta 1 \delta E \text{ (adult form)}$	(α3) ₂ (β2) ₃	(α4) ₂ (β2) ₃	(α7) ₅	-
Main synaptic location	Skeletal neuromuscular junction: mainly postsynaptic	Autonomic ganglia: mainly postsynaptic	Many brain regions: pre- and postsynaptic	Many brain regions: pre- and postsynaptic	-
Membrane response	_	Excitatory. Increased cation permeability (mainly Na ⁺ , K ⁺)	Pre- and postsynaptic excitation. Increased cation permeability (mainly Na $^+$, K $^+$)	Pre- and postsynaptic excitation. Increased cation permeability	$\left(\alpha7\right)_{5}$ receptor produces large Ca ²⁺ entry, evoking transmitter release
Agonists	Acetylcholine Carbachol Succinylcholine		Nicotine Epibatidine Acetylcholine Cytosine Varenicline ^b	Epibatidine Dimethylphenylpiperazinium Varenicline ^b	$\left(\alpha4\right)_{2}\!\left(\beta2\right)_{3}$ is main brain 'nicotine receptor' See <u>Ch. 38</u>
Antagonists	Tubocurarine Pancuronium Atracurium V		Mecamylamine Methylaconitine	α-Bungarotoxin α-Conotoxin Methylaconitine	

	M ₁ ('neural')	M ₂ ('cardiac')	M ₃ ('glandular/smooth muscle')	M ₄	M ₅
Main locations	Autonomic ganglia Glands: gastric, salivary, lacrimal, etc. Cerebral cortex	Heart: atria CNS: widely distributed	Exocrine glands: gastric, salivary, etc. Smooth muscle: gastrointestinal tract, eye, airways, bladder Blood vessels: endothelium	CNS	CNS: very localised expression in substantia nigra Salivary glands Iris/ciliary muscle
Cellular response	↑ IP ₃ , DAG Depolarisation Excitation (slow epsp) ↓ K ⁺ conductance		↑ IP ₃ Stimulation ↑ [Ca ²⁺] _i	↓ cAMP Inhibition	↑ IP ₃ Excitation
Functional response	CNS excitation (? improved cognition) Gastric secretion	Cardiac inhibition Neural inhibition Central muscarinic effects (e.g. tremor, hypothermia)	Gastric, salivary secretion Gastrointestinal smooth muscle contraction Ocular accommodation Vasodilatation	Enhanced locomotion	Not known
Non-selective agonists (see also <u>Table 13.3</u>)	Acetylcholine Carbachol Oxotremorine Pilocarpine Bethanechol				
Selective agonists	McNA343		Cevimeline		
Non-selective antagonists (see also <u>Table 13.5</u>)	Atropine Dicycloverine Tolterodine Oxybutynin Ipratropium				
Selective antagonists	Pirenzepine Mamba toxin MT7	Gallamine (see <u>p. 164</u>)	Darifenacin	Mamba toxin MT3	



Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.

Compound	Structure	Receptor	specificity	Hydrolysis by cholinesterase	Clinical uses
Muscarinic	Nicotinic				
Acetylcholine	H ₂ C CH ₃ CH ₃ CH ₃	***	***	***	None
Carbachol	H ₂ N CH ₃ CH ₃ CH ₃	**	***	-	None
Methacholine	H ₃ C CH ₃ CH ₃ N CH ₃ CH ₃ CH ₃	***	+	**	None
Bethanechol	H ₂ N CH ₃ CH ₅ CH ₅ CH ₅ CH ₅	***	-	-	Treatment of bladder and gastrointestinal hypotonia ^a
Muscarine		***	-	-	None ^b
Pilocarpine		++	-	-	Glaucoma
Oxotremorine		++	-	-	None
Cevimeline		++c	-	-	Sjögren's syndrome (to increase salivary and lacrimal secretion)

^aEssential to check that bladder neck is not obstructed.

Drug ^a	Mechanism	Notes	See Chapter
Timolol, carteolol	β-Adrenoceptor antagonist	Given as eye drops but may still cause systemic side effects: bradycardia, bronchoconstriction	<u>14</u>
Acetazolamide, dorzolamide	Carbonic anhydrase inhibitor	Acetazolamide is given systemically Side effects include diuresis, loss of appetite, tingling, neutropenia Dorzolamide is used as eye drops Side effects include bitter taste and burning sensation	<u>28</u>
Clonidine, apraclonidine	α ₂ Adrenoceptor agonist	Used as eye drops	<u>14</u>
Latanoprost	Prostaglandin analogue	Can alter iris pigmentation	<u>17</u>
Pilocarpine	Muscarinic agonist	Used as eye drops	This chapter
Ecothiophate	Anticholinesterase	Used as eye drops Can cause muscle spasm and systemic effects	This chapter
		Can cause muscle spasm and systemic effects	


^a The most important drugs are shown in **bold**.

^bCause of one type of mushroom poisoning.

^CSelective for M₃ receptors.



Irreversible anticholinesterase



Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.


Drug	Structure	Duration of action	Main site of action	Notes
Edrophonium	HO————————————————————————————————————	Short	ИМЛ	Used mainly in diagnosis of myasthenia gravis Too short-acting for therapeutic use
Neostigmine	H ₀ C N CH ₀ CH ₀ CH ₀	Medium	ММЈ	Used intravenously to reverse competitive neuromuscular block Used orally in treatment of myasthenia gravis Visceral side effects
Physostigmine	H ₃ C CH ₃ CH ₃	Medium	P	Used as eye drops in treatment of glaucoma
Pyridostigmine	H ₃ C N O N CH ₃	Medium	NMJ	Used orally in treatment of myasthenia gravis Better absorbed than neostigmine and has longer duration of action
Dyflos	HIC PF	Long	Р	Highly toxic organophosphate, with very prolonged action Has been used as eye drops for glaucoma
Ecothiophate	H ₀ C O CH ₅ N © CH ₅ CH ₅ CH ₅	Long	Р	Used as eye drops in treatment of glaucoma Prolonged action; may cause systemic effects
Parathion	H ₃ C	Long	-	Converted to active metabolite by replacement of sulfur by oxygen Used as insecticide but commonly causes poisoning in humans

Other anticholinesterase drugs developed for the treatment of dementia are described in <u>Chapter 39</u>. NMJ, neuromuscular junction; P, postganglionic parasympathetic junction.


Compound	Pharmacological properties	Clinical uses	Notes
Atropine	Non-selective antagonist Well absorbed orally CNS stimulant	Adjunct for anaesthesia (reduced secretions, bronchodilatation) Anticholinesterase poisoning Bradycardia Gastrointestinal hypermotility (antispasmodic)	Belladonna alkaloid Main side effects: urinary retention, dry mouth, blurred vision Dicycloverine (dicyclomine) is similar and used mainly as antispasmodic agent
Hyoscine	Similar to atropine CNS depressant	As atropine Motion sickness	Belladonna alkaloid (also known as scopolamine) Causes sedation; other side effects as atropine
Hyoscine butylbromide	Similar to atropine but poorly absorbed and lacks CNS effects Significant ganglion-blocking activity	Mainly for gastrointestinal hypermotility	Quaternary ammonium derivative Similar drugs include atropine methonitrate, propantheline
Tiotropium	Similar to atropine methonitrate Does not inhibit mucociliary clearance from bronchi	By inhalation for asthma, bronchitis	Quaternary ammonium compound Ipratropium similar
Tropicamide	Similar to atropine May raise intraocular pressure	Ophthalmic use to produce mydriasis and cycloplegia (as eye drops) Short acting	-
Cyclopentolate	Similar to tropicamide	As tropicamide (long acting)	-
Pirenzepine	Selective for M ₁ receptors Inhibits gastric secretion by action on ganglion cells Little effect on smooth muscle or CNS	Peptic ulcer	Fewer side effects than other muscarinic antagonists Largely superseded by other antiulcer drugs (see <u>Ch. 29</u>)
Darifenacin	Selective for M ₃ receptors	Urinary incontinence	Few side effects

^aFor chemical structures, see Brunton L et al. 2006 Goodman and Gilman's pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York.

Other non-selective muscarinic antagonists in clinical use, with very similar actions and side effects, include oxybutynin, tolterodine, fesoterodine, solifenacin and trospium-an example of me-too development by pharmacetical companies.





HO



Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.

Tissues and effects	α ₁	α ₂	β ₁	β_2	β_3
Smooth muscle					
Blood vessels	Constrict	Constrict/dilate	-	Dilate	-
Bronchi	Constrict	-	-	Dilate	-
Sastrointestinal tract	Relax	Relax (presynaptic effect)	-	Relax	-
Sastrointestinal sphincters	Contract	-	-	-	-
Jterus	Contract	-	-	Relax	-
Bladder detrusor	-	-	-	Relax	-
Bladder sphincter	Contract	-	-	-	-
Seminal tract	Contract	-	-	Relax	-
ris (radial muscle)	Contract	-	-	-	-
Ciliary muscle	-	-	-	Relax	-
leart					
Rate	-	-	Increase	Increase ^a	-
orce of contraction	-	-	Increase	Increase ^a	-
Skeletal muscle	-	-	-	Tremor Increased muscle mass and speed of contraction Glycogenolysis	Thermogenesis
iver	Glycogenolysis	-	-	Glycogenolysis	-
at	-	-	-	-	Lipolysis Thermogenesis
Pancreatic islets	-	Decrease insulin secretion	-	-	-
lerve terminals					
Adrenergic	-	Decrease release	-	Increase release	-
Cholinergic	-	Decrease release	-	-	-
Salivary gland	K ⁺ release	-	Amylase secretion	-	-
Platelets	-	Aggregation	-	-	-
flast cells	-	-	-	Inhibition of histamine release	-
Brain stem	-	Inhibits sympathetic outflow	-	-	-
Second messengers and effectors	Phospholipase C activation ↑ Inositol trisphosphate ↑ Diacylglycerol ↑ Ca ²⁺	↓ cAMP ↓ Calcium channels ↑ Potassium channels	↑ cAMP	↑ cAMP	↑ cAMP
Agonist potency order	NA ≥ A >> ISO	A > NA >> ISO	ISO > NA > A	ISO > A > NA	ISO > NA = A
Selective agonists	Phenylephrine	Clonidine	Dobutamine	Salbutamol	BRL 37344
	Methoxamine		Xamoterol	Terbutaline	
				Salmeterol	
				Formoterol	
				Clenbuterol	
Selective antagonists	Prazosin	Yohimbine	Atenolol	Butoxamine	-
-	Doxazocin	Idazoxan	Metoprolol		







Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.

	Neuronal (NET)	Extraneuronal (EMT)	Vesicular (VMAT)
Transport of NA (rat heart)	1.2	100	-
V _{max} (nmol/g per min)			
K _m (μmoVI)	0.3	250	~0.2
Specificity	NA > A > ISO	A > NA > ISO	NA = A = ISO
Location	Neuronal membrane	Non-neuronal cell membrane (smooth muscle, cardiac muscle, endothelium)	Synaptic vesicle membrane
Other substrates	Tyramine	(+)-Noradrenaline	Dopamine
	Methylnoradrenaline	Dopamine	5-Hydroxytryptamine
	Adrenergic neuron-blocking drugs (e.g. guanethidine)	5-Hydroxytryptamine Histamine	Guanethidine MPP+ (see <u>Ch. 37</u>)
	Amphetamine ^a		
Inhibitors	Cocaine	Normetanephrine	Reserpine
	Tricyclic antidepressants (e.g. desipramine)	Steroid hormones (e.g. corticosterone)	Tetrabenazine
	Phenoxybenzamine	Phenoxybenzamine	
	Amphetamine ^a		


^aAmphetamine is transported slowly, so acts both as a substrate and as an inhibitor of noradrenaline uptake. For details, see <u>Gainetdinov & Caron (2003)</u>. A, adrenaline; ISO, isoprenaline; NA, noradrenaline.



Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.




Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.




Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.

Parasympathetic


Sympathetic



A Presynaptic inhibition




(B) Heterotropic presynaptic inhibition




Noradrenergic /cholinergic nerve terminals in the heart

(C) Postsynaptic synergism









 $^{\circ}$

Mediator	Receptor type	
ACh	Musc.	
NA/A	α_2	
5-HT	5-HT ₁	Receptor type Mediator
Adenosine	A ₁	
PGE	EP	$ \bigcirc \bigcirc$
Histamine	H ₂	All Aligible Isli II
Enkephalin	δ	
Dopamine	D ₂	NA release
ATP	P2X / P2Y	M.
Endocannabinoids	CBI	

Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.





Rang et al: Rang & Dale's Pharmacology, 7e Copyright © 2011 by Churchill Livingstone, an imprint of Elsevier Ltd. All rights reserved.